SLC5A2 and rectal cancer: The suggestive causality between SGLT2 inhibition with oral cavity and pharyngeal cancer (beta: -0.010 [-0.017, -0.002], P = 0.011), small intestinal cancer (beta: 0.004 [0.000, 0.009], P = 0.037), rectal cancer (beta: -0.011 [-0.019, -0.004], P = 0.005), ovarian cancer (beta: -2.304 [-4.550, -0.058], P = 0.044) and multiple myeloma (beta: -0.008 [-0.014, -0.001], P = 0.017) was also noted (Figure 2, Supplementary Table S4).